Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Neurological Disorders Channel
Reported January 30, 2012

Investigating Fingolimod for Multiple Sclerosis

(Ivanhoe Newswire)-- Many of us have heard of or know someone with the dreadful disease known as multiple sclerosis. Affecting approximately 400,000 people in the United States and 2.5 million people worldwide, multiple sclerosis is still incurable and has few effective treatments available.

Patients affected by multiple sclerosis are hindered on a daily basis by physical ailments, including fatigue, pain, and difficulty with mobility, as well as problems with social functioning and impaired mood.

The Food and Drug Administration (FDA) approved fingolimod in September 2010, as a treatment targeted at reducing the frequency of clinical exacerbations and postponing the progression of physical disability in patients with relapsing forms of multiple sclerosis. Fingolimod was the first oral therapy approved by the FDA for the treatment of multiple sclerosis.

Multiple sclerosis is an autoimmune disease in which lymphocytes move out of lymph nodes into the circulation, cross the blood–brain barrier, and aggressively target putative myelin antigens in the central nervous system, causing inflammation, demyelination, neuroaxonal injury, astrogliosis, and eventually neurodegeneration.

Although patients with multiple sclerosis that are treated with fingolimod have a reduction in the overall mean lymphocyte count, the effects on lymphocyte subsets are rather specific: the drug blocks the exit of naive and central memory lymphocytes, but not effector memory T cells, from the lymph node.

The effectiveness of oral fingolimod for the treatment of multiple sclerosis was investigated in a study consisting of two large, phase 3, double-blind, randomized trials involving patients with relapsing–remitting disease. Patients with progressive forms of multiple sclerosis were not included in the study.

The study consisted of 1272 patients who were randomly assigned to receive oral fingolimod at a dose of 0.5 mg daily or 1.25 mg daily or placebo tablets for 2 years. 22 Neurologic evaluations included measures of acute relapses and disability.

Fingolimod was shown to reduce the frequency of clinical exacerbations and delay the progression of physical disability in patients with reoccurring forms of multiple sclerosis. Fingolimod was also associated with a reduced amount of new or enlarging lesions on T2-weighted images and of gadolinium-enhancing lesions on MRI at year 2. Reductions in whole-brain volume were smaller with fingolimod than with placebo at both 12 and 24 months.

Despite the positive results in the trials, researchers believe that until additional long-term safety information is available, fingolimod therapy should be considered only for patients who have had recent inflammatory disease activity and those who do not benefit from or cannot tolerate alternative disease-modifying therapies.

SOURCE: New England Journal of Medicine, January 2012


Related Articles in Latest Medical News:

[ Back to Neurological Disorders Channel Home ]

MEDICAL ALERT!
Stay up to date on Neurological Disorders. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Advertisement

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News